Literature DB >> 16862329

Seroepidemiological study of herpes simplex virus type 2 in patients with the acquired immunodeficiency syndrome in the city of Niterói, Rio de Janeiro, Brazil.

Flávia Cunha Santos1, Solange Artimos de Oliveira, Sérgio Setúbal, Luiz Antonio Bastos Camacho, Tereza Faillace, José Paulo Gagliardi Leite, Luis Guillermo Coca Velarde.   

Abstract

This study was designed to determine the seroprevalence of herpes simplex virus type 2 (HSV-2) and to evaluate its association with age, sex as well as other demographic and behavioural factors in 150 human immunodeficiency virus (HIV) positive adults patients attending the general medical outpatient ward for routine care of Niterói, state of Rio de Janeiro, Brazil. Serum samples were screened for HSV-2 antibodies using an indirect ELISA. Eighty-three patients were men (mean age: 38.8) and 67 were women (mean age: 35.4). The estimated prevalence of HSV-2 was 52% (95% CI: 44-60%) and it was higher among men (53%) than among women (50.7%). Overall, the age of first sexual intercourse and past history of genital herpes were associated with HSV-2 seropositivity. Analysis by gender disclosed significant association of number of lifetime sex partners only among men. Although HSV-2 antibodies were frequent in the study group, genital herpes was reported by 21.8% of the HSV-2 positive subjects, indicating low awareness of the HSV-2 infection. These results may have public health importance for Brazil as the high rate of HSV-2 infection may act as a cofactor of HIV transmission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862329     DOI: 10.1590/s0074-02762006000300016

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  8 in total

1.  Seroepidemiology of herpes simplex virus type 2 (HSV2) in HIV infected patients in Kermanshah-Iran.

Authors:  Alireza Janbakhash; Feizollah Mansouri; Siavash Vaziri; Babak Sayad; Mandana Afsharian; Ahmadreza Abedanpor
Journal:  Caspian J Intern Med       Date:  2012

2.  Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.

Authors:  Jason D Walker; Inder Sehgal; Konstantin G Kousoulas
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  Serological Profile of HSV-2 in STD Patients: Evaluation of Diagnostic Utility of HSV-2 IgM and IgG Detection.

Authors:  V P Amudha; G Sucilathangam; B Cinthujah; C Revathy
Journal:  J Clin Diagn Res       Date:  2014-12-05

4.  Serum HSV-1 and 2 IgM in Sexually Transmitted Diseases - More for Screening Less for Diagnosis: An Evaluation of Clinical Manifestation.

Authors:  Dharmishtha G Tada; Nita Khandelwal
Journal:  J Glob Infect Dis       Date:  2012-07

5.  Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Beatriz Grinsztejn; Pedro Cahn; Sharon L Walmsley
Journal:  Trials       Date:  2010-11-24       Impact factor: 2.279

6.  Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso
Journal:  BMC Infect Dis       Date:  2009-04-01       Impact factor: 3.090

7.  Etiology of Vaginal/Cervical Discharge Syndrome: Analysis of Data from a Referral Laboratory in Eastern India.

Authors:  Ishita Ghosh; Bandhan Paul; Nibedita Das; Debabrata Bandyopadhyay; Manas Kumar Chakrabarti
Journal:  Indian J Dermatol       Date:  2018 Nov-Dec       Impact factor: 1.494

8.  Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Beatriz Grinsztejn; José Valdez Madruga; Maria Ines Figueroa; Pedro Cahn; Simon E Barton; Amanda Clarke; Julie Fox; Wendy Zubyk; Sharon L Walmsley
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.